Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
ALK+ and ROS1+ NSCLC: Optimising patient outcomes
Date
14 Sep 2020Session
Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencingPresenters
Todd BauerAuthors
T. BauerAuthor affiliations
- Sarah Cannon Research Institute, 37203 - Nashville/US
Resources
Resources from the same session
Welcome and introduction
Presenter: Rosario Garcia Campelo
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
Latest updates in molecular testing in NSCLC
Presenter: Justin Gainor
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
EGFR+ NSCLC: A personalised sequencing approach
Presenter: Jesus Corral Jaime
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast